The Listing of Claims

This listing of claims will replace all prior versions and listings of claims in the application.

1. (Currently Amended) A compound of the formula I:



(I)

or pharmaceutically acceptable salts thereof, wherein

Z is hydrogen, $(C_3\text{-}C_7$ cycloalkyl$)_{0\text{-}1}(C_1\text{-}C_8$ alkyl$)$-, $(C_3\text{-}C_7$ cycloalkyl$)_{0\text{-}1}(C_2\text{-}C_8$ alkenyl$)$-, alkoxyalkoxyalkyl, $(C_3\text{-}C_7$ cycloalkyl$)_{0\text{-}1}(C_2\text{-}C_8$ alkynyl$)$- or $(C_3\text{-}C_7$ cycloalkyl$)$-, wherein each of said groups is optionally substituted with 1, 2, or 3 R_Z groups, wherein 1 or 2 methylene groups within said $(C_3\text{-}C_7$ cycloalkyl$)_{0\text{-}1}(C_1\text{-}C_8$ alkyl$)$-, $(C_3\text{-}C_7$ cycloalkyl$)_{0\text{-}1}(C_2\text{-}C_8$ alkenyl$)$-, $(C_3\text{-}C_7$ cycloalkyl$)_{0\text{-}1}(C_2\text{-}C_8$ alkynyl$)$- or $(C_3\text{-}C_7$ cycloalkyl$)$- groups are optionally replaced with -(C=O)-;

wherein R_Z at each occurrence is independently halogen, -OH, -SH, -CN, $-CF_3$, $-OCF_3$, $C_1\text{-}C_6$ alkoxy, $C_3\text{-}C_7$ cycloalkyl, $C_3\text{-}C_7$ cycloalkoxy or $-NR_{100}R_{101}$;

where R_{100} and R_{101} are independently H, $C_1\text{-}C_6$ alkyl, phenyl, $CO(C_1\text{-}C_8$ alkyl$)$ or $SO_2C_1\text{-}C_8$ alkyl;

X is -(C=O)-, ~~-(C=S)-~~ $-(SO_2)$-;

R_1 is $C_1\text{-}C_{10}$ alkyl optionally substituted with 1, 2, or 3 groups independently selected from halogen, -OH, =O, -SH, -CN, $-CF_3$, $-OCF_3$, $-C_{3\text{-}7}$ cycloalkyl, $-C_1\text{-}C_4$ alkoxy, amino, mono-dialkylamino, aryl, heteroaryl, and heterocycloalkyl, wherein each aryl group is optionally substituted with 1, 2 or 3 R_{50} groups;

R_{50} is selected from halogen, OH, SH, CN, $-CO\text{-}(C_1\text{-}C_4$ alkyl$)$, $-NR_7R_8$, $-S(O)_{0\text{-}2}\text{-}(C_1\text{-}C_4$ alkyl$)$, $C_1\text{-}C_6$ alkyl, $C_2\text{-}C_6$ alkenyl, $C_2\text{-}C_6$ alkynyl, $C_1\text{-}C_8$ alkoxy, -O-benzyl, alkenyloxy, alkoxyalkoxyalkoxy, and $C_3\text{-}C_8$ cycloalkyl;

wherein the alkyl, alkenyl, alkynyl, alkoxy and cycloalkyl groups are optionally substituted with 1 or 2 substituents independently selected from $C_1\text{-}C_4$ alkyl, halogen, OH, $-NR_5R_6$, CN, $C_1\text{-}C_4$ haloalkoxy, NR_7R_8, and $C_1\text{-}C_4$ alkoxy;

R_5 and R_6 are independently H or $C_1\text{-}C_6$ alkyl; or

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

PAGE 3/18 * RCVD AT 1/8/2007 1:02:31 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/3 * DNIS:2738300 * CSID:312 913 0002 * DURATION (mm-ss):04-28

R_5 and R_6 and the nitrogen to which they are attached form a 5 or 6 membered heterocycloalkyl ring; and

R_7 and R_8 are independently selected from H; -C_1-C_4 alkyl optionally substituted with 1, 2, or 3 groups independently selected from -OH, -NH_2, and halogen; -C_3-C_6 cycloalkyl; -(C_1-C_4 alkyl)-O-(C_1-C_4 alkyl); -C_2-C_4 alkenyl; and -C_2-C_4 alkynyl;

wherein each heteroaryl is optionally substituted with 1 or 2 R_{50} groups;

wherein each heterocycloalkyl group is optionally substituted with 1 or 2 groups that are independently R_{50} or =O;

R_2 and R_3 are independently selected from

-H;

-F;

-C_1-C_6 alkyl optionally substituted with a substituent selected from -F, -OH, -C≡N, -CF_3, C_1-C_3 alkoxy, and –NR_5R_6;

-$(CH_2)_{0-2}$-R_{17};

-$(CH_2)_{0-2}$-R_{18};

-C_2-C_6 alkenyl or C_2-C_6 alkynyl, wherein each is optionally substituted with an indepdent substituent selected from -F, -OH, ~~-OH,~~ -C≡N, -CF_3 and C_1-C_3 alkoxy;

-$(CH_2)_{0-2}$-C_3-C_7 cycloalkyl, optionally substituted an independent substituent selected from -F, -OH, , -C≡N, -CF_3, C_1-C_3 alkoxy and –NR_5R_6; or

wherein R_2, R_3 and the carbon to which they are attached form a carbocycle of three thru seven carbon atoms, wherein one carbon atom is optionally replaced by a group selected from –O-, -S-, -SO_2-, or -NR_7-;

where R_{17} at each occurrence is an aryl group selected from phenyl, 1-naphthyl, 2-naphthyl , indanyl, indenyl, dihydronaphthyl and tetralinyl, wherein said aryl groups are optionally substituted with one or two groups that are independently

-C_1-C_3 alkyl; -C_1-C_4 alkoxy; CF_3; or

-C_2-C_6 alkenyl or -C_2-C_6 alkynyl each of which is optionally substituted with one substituent selected from F, OH, C_1-C_3 alkoxy; or

-halogen;

-OH;

-C≡N;

-C_3-C_7 cycloalkyl;

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

PAGE 4/18 * RCVD AT 1/8/2007 1:02:31 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/3 * DNIS:2738300 * CSID:312 913 0002 * DURATION (mm-ss):04-28

-CO-(C_1-C_4 alkyl);

-SO_2-(C_1-C_4 alkyl);

where R_{18} is a heteroaryl group selected from pyridinyl, pyrimidinyl, quinolinyl, indolyl, pryidazinyl, pyrazinyl, isoquinolyl, quinazolinyl, quinoxalinyl, phthalazinyl, imidazolyl, isoxazolyl, oxazolyl, thiazolyl, furanyl, thienyl, pyrrolyl, oxadiazolyl or thiadiazolyl, wherein each of said heteroaryl groups is optionally substituted with one or two groups that are independently

-C_1-C_6 alkyl optionally substituted with one substituent selected from OH, C≡N, CF_3, C_1-C_3 alkoxy, and -NR_5R_6;

wherein R_{15} is selected from hydrogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 alkoxy C_1-C_6 alkyl, hydroxy C_1-C_6 alkyl, halo C_1-C_6 alkyl, benzyl, -$C(O)_2$-benyl, and alkoxycarbonyl, wherein the alkyl and phenyl portion of each is unsubstituted or substituted with 1, 2, 3, or 4 groups independently selected from halogen, C_1-C_6 alkyl, hydroxy, C_1-C_6 alkoxy, NH_2, and -R_{26}-R_{27};

wherein R_{26} is selected from a bond, –C(O)-, -SO_2-, -CO_2-, -C(O)NR_5-, and -NR_5C(O)-,

wherein R_{27} is selected from C_1-C_6 alkyl, C_1-C_6 alkoxy, aryl C_1-C_6 alkyl, heterocycloalkyl, and heteroaryl, wherein each of the above is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently C_1-C_4 alkyl, C_1-C_4 alkoxy, halogen, haloalkyl, hydroxyalkyl, -NR_5R_6, -C(O)NR_5R_6;

wherein R_C is selected from

heteroaryl;

heterocycloalkyl;

-heteroaryl-aryl;

-heteroaryl-heterocycloalkyl;

-heteroaryl-heteroaryl;

-heterocycloalkyl-heteroaryl;

-heterocycloalkyl-heterocycloalkyl;

-heterocycloalkyl-aryl;

wherein each aryl group is optionally substituted with 1, 2, 3 or 4 R_{200} groups;

wherein each heteroaryl group is optionally substituted with 1, 2, 3, or 4 R_{200};

wherein each heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 R_{210};

wherein R_{200} at each occurrence is independently selected from

-C_1-C_6 alkyl optionally substituted with 1, 2, or 3 R_{205} groups;

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

PAGE 5/18 * RCVD AT 1/8/2007 1:02:31 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/3 * DNIS:2738300 * CSID:312 913 0002 * DURATION (mm-ss):04-28

-OH;

$-NO_2$;

-halogen;

-C≡N;

-CHO;

$-(CH_2)_{0-4}$-CO-$NR_{220}R_{225}$;

$-(CH_2)_{0-4}$-CO-(C_1-C_8 alkyl);

$-(CH_2)_{0-4}$-CO-(C_2-C_8 alkenyl);

$-(CH_2)_{0-4}$-CO-(C_2-C_8 alkynyl);

$-(CH_2)_{0-4}$-CO-(C_3-C_7 cycloalkyl);

$-(CH_2)_{0-4}$-$(CO)_{0-1}$-aryl;

$-(CH_2)_{0-4}$-$(CO)_{0-1}$-heteroaryl;

$-(CH_2)_{0-4}$-$(CO)_{0-1}$-heterocycloalkyl;

$-(CH_2)_{0-4}$-CO_2R_{215};

$-(CH_2)_{0-4}$-SO_2-$NR_{220}R_{225}$;

$-(CH_2)_{0-4}$-$S(O)_{0-2}$-(C_1-C_8 alkyl);

$-(CH_2)_{0-4}$-$S(O)_{0-2}$-(C_3-C_7 cycloalkyl);

$-(CH_2)_{0-4}$-N(H or R_{215})-CO_2R_{215};

$-(CH_2)_{0-4}$-N(H or R_{215})-SO_2-R_{220};

$-(CH_2)_{0-4}$-N(H or R_{215})-CO-$N(R_{215})_2$;

$-(CH_2)_{0-4}$-N(-H or R_{215})-CO-R_{220};

$-(CH_2)_{0-4}$-$NR_{220}R_{225}$;

$-(CH_2)_{0-4}$-O-CO-(C_1-C_6 alkyl);

$-(CH_2)_{0-4}$-O-(R_{215});

$-(CH_2)_{0-4}$-S-(R_{215});

$-(CH_2)_{0-4}$-O-(C_1-C_6 alkyl optionally substituted with 1, 2, 3, or 5 -F);

-C_2-C_6 alkenyl optionally substituted with 1 or 2 R_{205} groups;

-C_2-C_6 alkynyl optionally substituted with 1 or 2 R_{205} groups;

and

$-(CH_2)_{0-4}$- C_3-C_7 cycloalkyl;

wherein each aryl group included within R_{200} is optionally substituted with 1, 2, or 3 groups that are independently

-R_{205},

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

PAGE 6/18 * RCVD AT 1/8/2007 1:02:31 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/3 * DNIS:2738300 * CSID:312 913 0002 * DURATION (mm-ss):04-28

-R_{210} or

-C_1-C_6 alkyl substituted with 1, 2, or 3 groups that are independently R_{205} or R_{210};

wherein each heterocycloalkyl group included within R_{200} is optionally substituted with 1, 2, or 3 groups that are independently R_{210};

wherein each heteroaryl group included within R_{200} is optionally substituted with 1, 2, or 3 groups that are independently

-R_{205},

-R_{210}, or

-C_1-C_6 alkyl substituted with 1, 2, or 3 groups that are independently

-R_{205} or

-R_{210};

wherein R_{205} at each occurrence is independently selected from

-C_1-C_6 alkyl,

-C_2-C_6 alkenyl,

-C_2-C_6 alkynyl,

-C_1-C_6 haloalkoxy

-$(CH_2)_{0-3}(C_3$-C_7 cycloalkyl)

-halogen,

-$(CH_2)_{0-6}$-OH,

-O-phenyl,

-alkenyl-phenyl,

-SH,

-$(CH_2)_{0-6}$-C≡N,

-$(CH_2)_{0-6}$-C(=O)$NR_{235}R_{240}$

-CF_3,

-$C(O)_2$-benzyl,

-C_1-C_6 alkoxy, and

-$NR_{235}R_{240}$,

wherein R_{210} at each occurrence is independently selected from

-C_1-C_6 alkyl optionally substituted with 1, 2, or 3 R_{205} groups;

-C_2-C_6 alkenyl optionally substituted with 1, 2, or 3 R_{205} groups;

-C_2-C_6 alkynyl optionally substituted with 1, 2, or 3 R_{205} groups;

-halogen;

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

PAGE 7/18 * RCVD AT 1/8/2007 1:02:31 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/3 * DNIS:2738300 * CSID:312 913 0002 * DURATION (mm-ss):04-28

-C_1-C_6 alkoxy;

-C_1-C_6 haloalkoxy;

-$NR_{220}R_{225}$;

-OH;

-C≡N;

-C_3-C_7 cycloalkyl optionally substituted with 1, 2, or 3 R_{205} groups;

-CO-(C_1-C_4 alkyl);

-SO_2-$NR_{235}R_{240}$;

-CO-$NR_{235}R_{240}$;

-SO_2-(C_1-C_4 alkyl); and

=O; wherein

wherein R_{215} at each occurrence is independently selected from

-C_1-C_6 alkyl,

-$(CH_2)_{0-2}$-(aryl),

-C_2-C_6 alkenyl,

-C_2-C_6 alkynyl,

-C_3-C_7 cycloalkyl,

-$(CH_2)_{0-2}$-(heteroaryl), and

-$(CH_2)_{0-2}$-(heterocycloalkyl);

wherein the aryl group included within R_{215} is optionally substituted with 1, 2, or 3 groups that are independently

-R_{205} or

-R_{210};

wherein the heterocycloalkyl group included within R_{215} is optionally substituted with 1, 2, or 3 R_{210};

wherein each heteroaryl group included within R_{215} is optionally substituted with 1, 2, or 3 R_{210};

wherein R_{220} and R_{225} at each occurrence are independently selected from

-H,

-C_1-C_6 alkyl,

-hydroxy C_1-C_6 alkyl,

-amino C_1-C_6 alkyl,

-halo C_1-C_6 alkyl,

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

PAGE 8/18 * RCVD AT 1/8/2007 1:02:31 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/3 * DNIS:2738300 * CSID:312 913 0002 * DURATION (mm-ss):04-28

-$(CH_2)_{0-2}$-(C_3-C_7 cycloalkyl),

-(C_1-C_6 alkyl)-O-(C_1-C_3 alkyl),

-C_2-C_6 alkenyl,

-C_2-C_6 alkynyl,

-aryl,

-heteroaryl, and

-heterocycloalkyl;

wherein the aryl, heteroaryl or heterocycloalkyl group included within R_{220} and R_{225} is optionally substituted with 1, 2, or 3 R_{270} groups,

wherein R_{270} at each occurrence is independently

-R_{205},

-C_1-C_6 alkyl optionally substituted with 1, 2, or 3 R_{205} groups;

-C_2-C_6 alkenyl optionally substituted with 1, 2, or 3 R_{205} groups;

-C_2-C_6 alkynyl optionally substituted with 1, 2, or 3 R_{205} groups;

-halogen;

-C_1-C_6 alkoxy;

-C_1-C_6 haloalkoxy;

-$NR_{235}R_{240}$;

-OH;

-C≡N;

-C_3-C_7 cycloalkyl optionally substituted with 1, 2, or 3 R_{205} groups;

-CO-(C_1-C_4 alkyl);

-SO_2-$NR_{235}R_{240}$;

-CO-$NR_{235}R_{240}$;

-SO_2-(C_1-C_4 alkyl); and

=O;

wherein R_{235} and R_{240} at each occurrence are independently

-H, ~~or~~

-C_1-C_6 alkyl; or

-phenyl.

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

PAGE 9/18 * RCVD AT 1/8/2007 1:02:31 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/3 * DNIS:2738300 * CSID:312 913 0002 * DURATION (mm-ss):04-28

2. (Original) A compound according to claim 1, wherein Z is (C_3-C_7 cycloalkyl)$_{0-1}$(C_1-C_6 alkyl)-, (C_3-C_7 cycloalkyl)$_{0-1}$(C_2-C_6 alkenyl)-, (C_3-C_7 cycloalkyl)$_{0-1}$(C_2-C_6 alkynyl)- or (C_3-C_7 cycloalkyl)-, wherein each of said groups is optionally substituted with 1, 2, or 3 R_Z groups;

wherein, R_Z at each occurrence is independently halogen, -OH, -CN, C_1-C_6 alkoxy, C_3-C_7 cycloalkyl, C_3-C_7 cycloalkoxy, -$NR_{100}R_{101}$;

where R_{100} and R_{101} are independently H, C_1-C_6 alkyl, phenyl, CO(C_1-C_6 alkyl) or SO_2C_1-C_6 alkyl.

3. (Original) A compound according to claim 1, wherein X is –(C=O)-.

4. (Original) A compound according to claim 3, wherein Z is H.

5. (Original) A compound according to claim 1, wherein R_1 is C_1-C_{10} alkyl optionally substituted with 1 or 2 groups independently selected from halogen, -OH, =O, -CF_3, -OCF_3, -C_{3-7} cycloalkyl, -C_1-C_4 alkoxy, amino or aryl, wherein the aryl group is optionally substituted with 1 or 2 R_{50} groups;

wherein R_{50} is selected from halogen, OH, -CO-(C_1-C_4 alkyl), -NR_7R_8, C_1-C_6 alkyl, C_1-C_6 alkoxy and C_3-C_8 cycloalkyl;

wherein the alkyl, alkoxy and cycloalkyl groups are optionally substituted with 1 or 2 substituents independently selected from C_1-C_4 alkyl, halogen, OH, -NR_5R_6, NR_7R_8, and C_1-C_4 alkoxy;

wherein R_5 and R_6 at are independently H or C_1-C_5 alkyl; or

wherein R_5 and R_6 and the nitrogen to which they are attached form a 5 or 6 membered heterocycloalkyl ring; and

wherein R_7 and R_8 are independently selected from -H; -C_1-C_4 alkyl optionally substituted with 1, 2, or 3 groups independently selected from -OH, -NH_2, and halogen; -C_3-C_6 cycloalkyl; -(C_1-C_4 alkyl)-O-(C_1-C_4 alkyl).

6. (Original) A compound according to claim 5, wherein R_1 is -CH_2-phenyl where the phenyl ring is optionally substituted with 1 or 2 groups independently selected from halogen, C_1-C_2 alkyl, C_1-C_2 alkoxy and hydroxy.

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

PAGE 10/18 * RCVD AT 1/8/2007 1:02:31 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/3 * DNIS:2738300 * CSID:312 913 0002 * DURATION (mm-ss):04-28

BEST AVAILABLE COPY

7. (Original) A compound according to claim 6, wherein R_1 is benzyl, 3-fluorobenzyl or 3,5-difluorobenzyl.

8. (Original) A compound according to claim 1, wherein R_{15} is H.

9. (Original) A compound according to claim 7, wherein R_{15} is H.

10. (Currently Amended) A compound according to claim 1 of the formula II:



(II)

wherein Z is hydrogen, -C_1-C_6 alkyl, -C_2-C_6 alkenyl, -C_2-C_6 alkynyl or -C_3-C_7 cycloalkyl, where each of said groups is optionally substituted with 1 or 2 R_Z groups, wherein 1 or 2 methylene groups within said -C_1-C_6 alkyl, -C_2-C_6 alkenyl, -C_2-C_6 alkynyl or -C_3-C_7 cycloalkyl groups are optionally replaced with -(C=O)-;

wherein R_Z at each occurrence is independently halogen, -OH, -CN, -CF_3, C_1-C_6 alkoxy, C_3-C_7 cycloalkyl, C_3-C_7 cycloalkoxy or -$NR_{100}R_{101}$;

where R_{100} and R_{101} are independently H, C_1-C_6 alkyl, phenyl, $CO(C_1$-C_6 alkyl) or SO_2C_1-C_6 alkyl;

wherein X is -C(=O)-;

wherein R_1 is C_1-C_{10} alkyl optionally substituted with 1 or 2 groups independently selected from halogen, -OH, =O, -CN, -CF_3, -OCF_3, -C_3-C_7 cycloalkyl, -C_1-C_4 alkoxy, amino, mono-dialkylamino, aryl, heteroaryl or heterocycloalkyl, wherein the aryl group is optionally substituted with 1 or 2 R_{50} groups;

where R_{50} is halogen, OH, CN, -CO-(C_1-C_4 alkyl), -NR_7R_8, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy and C_3-C_8 cycloalkyl;

where R_7 and R_8 are selected from H; -C_1-C_4 alkyl optionally substituted with 1, 2, or 3 groups selected from -OH, -NH_2 and halogen; -C_3-C_6 cycloalkyl; -(C_1-C_4 alkyl)-O-(C_1-C_4 alkyl); -C_2-C_4 alkenyl; and -C_2-C_4 alkynyl; and

wherein R_C is ~~selected from~~

heteroaryl; or

heterocycloalkyl;

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

PAGE 11/18 * RCVD AT 1/8/2007 1:02:31 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/3 * DNIS:2738300 * CSID:312 913 0002 * DURATION (mm-ss):04-28

BEST AVAILABLE COPY

where the heteroaryl group is optionally substituted with 1, 2, 3, or 4 R_{200} groups; and where the heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 R_{210} groups.

11. (Previously Presented) A compound according to claim 10, wherein

Z is -C_1-C_6 alkyl;

R_1 is C_1-C_{10} alkyl substituted with 1 phenyl group, where the phenyl group attached to the alkyl is optionally substituted with 1 or 2 R_{50} groups, where each R_{50} is independently halogen, OH, CN, or C_1-C_6 alkyl; and

R_C is heteroaryl, where the heteroaryl group is optionally substituted with 1 or 2 R_{200} groups.

12. (Currently Amended) A compound ~~according to claim 1 which~~ that is

N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(4R)-6-isopropyl-2,2-dioxido-3,4-dihydro-1H-isothiochromen-4-yl]amino}propyl)acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(4S)-6-isopropyl-2,2-dioxido-3,4-dihydro-1H-isothiochromen-4-yl]amino}propyl)acetamide;

N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(6-ethyl-2,2-dioxido-3,4-dihydro-1H-isothiochromen-4-yl)amino]-2-hydroxypropyl}acetamide;

~~N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(6-ethyl-2,2-dioxido-3,4-dihydro-1H-isothiochromen-4-yl)amino]-2-hydroxypropyl}acetamide;~~

N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(2,2-dioxido-3,4-dihydro-1H-isothiochromen-4-yl)amino]-2-hydroxypropyl}acetamide;

N-[1-(3,5-Difluoro-benzyl)-3-(6-ethyl-2,2-dioxo-2λ^6-isothiochroman-4-ylamino)-2-hydroxy-propyl]-2-methylamino-acetamide;

2-Amino-N-[1-(3,5-difluoro-benzyl)-3-(6-ethyl-2,2-dioxo-2λ^6-isothiochroman-4-ylamino)-2-hydroxy-propyl]-acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[6-ethyl-2-(methylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-4-yl]amino}-2-hydroxypropyl)acetamide;

N-[1-(3,5-Difluoro-benzyl)-3-(6-ethyl-2,2-dioxo-2λ^6-isothiochroman-4-ylamino)-2-hydroxy-propyl]-3-methyl-butyramide;

N-[1-(3,5-Difluoro-benzyl)-3-(6-ethyl-2,2-dioxo-2 λ^6-isothiochroman-4-ylamino)-2-hydroxy-propyl]-3-hydroxy-2,2-dimethyl-propionamide;

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

PAGE 12/18 * RCVD AT 1/8/2007 1:02:31 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/3 * DNIS:2738300 * CSID:312 913 0002 * DURATION (mm-ss):04-28

BEST AVAILABLE COPY

N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(2,2-dioxido-3,4-dihydro-1,2-benzoxathiin-4-yl)amino]-2-hydroxypropyl}acetamide;

N-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(6-iodo-3,4-dihydro-2H-chromen-4-yl)amino]propyl}acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(4S)-6-iodo-3,4-dihydro-2H-chromen-4-yl]amino}propyl)acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(4R)-6-iodo-3,4-dihydro-2H-chromen-4-yl]amino}propyl)acetamide;

N-[1-(3,5-Difluoro-benzyl)-3-(6-ethyl-2,2-dioxo-2 λ^6-isothiochroman-4-ylamino)-2-hydroxy-propyl]-3-hydroxy-propionamide;

N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(6-ethyl-2,2-dioxido-3,4-dihydro-1,2-benzoxathiin-4-yl)amino]-2-hydroxypropyl}acetamide;

~~N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(6-ethyl-2,2-dioxido-3,4-dihydro-1,2-benzoxathiin-4-yl)amino]-2-hydroxypropyl}acetamide;~~

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[4-(3-ethylphenyl)tetrahydro-2H-pyran-4-yl]amino}-2-hydroxypropyl)acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[(4S)-6-ethyl-3,4-dihydro-2H-chromen-4-yl]amino}-2-hydroxypropyl)acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[(4R)-6-ethyl-3,4-dihydro-2H-chromen-4-yl]amino}-2-hydroxypropyl)acetamide;

N-[1-(3,5-Difluoro-benzyl)-3-(6-ethyl-2,2-dioxo-2 λ^6-isothiochroman-4-ylamino)-2-hydroxy-propyl]-3-hydroxy-butyramide;

N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(6-ethyl-3,4-dihydro-1H-isothiochromen-4-yl)amino]-2-hydroxypropyl}acetamide;

~~N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[1-(3-isobutylisoxazol-5-yl)cyclopropyl]amino}propyl)acetamide;~~

N-[1-(3,5-Difluoro-benzyl)-3-(6-ethyl-2,2-dioxo-2 λ^6-isothiochroman-4-ylamino)-2-hydroxy-propyl]-2-phenyl-acetamide;

{[1-(3,5-Difluoro-benzyl)-3-(6-ethyl-2,2-dioxo-2 λ^6-isothiochroman-4-ylamino)-2-hydroxy-propylcarbamoyl]-methyl}-methyl-carbamic acid tert-butyl ester;

N-[1-(3,5-Difluoro-benzyl)-3-(6-ethyl-2,2-dioxo-2 λ^6-isothiochroman-4-ylamino)-2-hydroxy-propyl]-2-methyl-2-methylamino-propionamide;

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

PAGE 13/18 * RCVD AT 1/8/2007 1:02:31 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/3 * DNIS:2738300 * CSID:312 913 0002 * DURATION (mm-ss):04-28

BEST AVAILABLE COPY

N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(6-ethyl-2,2-dioxido-3,4-dihydro-1H-2,1-benzothiazin-4-yl)amino]-2-hydroxypropyl}acetamide;

N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(6-ethyl-2,2-dioxido-3,4-dihydro-1H-2,1-benzothiazin-4-yl)amino]-2-hydroxypropyl}acetamide;

N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(6-ethyl-3-methyl-2,2-dioxido-3,4-dihydro-1H-isothiochromen-4-yl)amino]-2-hydroxypropyl}acetamide;

N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(6-ethyl-3-methyl-2,2-dioxido-3,4-dihydro-1H-isothiochromen-4-yl)amino]-2-hydroxypropyl}acetamide;

N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(6-ethyl-1-methyl-1,2,3,4-tetrahydroquinolin-4-yl)amino]-2-hydroxypropyl}acetamide;

N-[1-(3,5-Difluoro-benzyl)-3-(6-ethyl-2,2-dioxo-2 λ^6-isothiochroman-4-ylamino)-2-hydroxy-propyl]-2-(1H-imidazol-4-yl)-acetamide;

N-[1-(3,5-Difluoro-benzyl)-3-(6-ethyl-2,2-dioxo-2 λ^6-isothiochroman-4-ylamino)-2-hydroxy-propyl]-propionamide;

~~N-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(4-ethylpyridin-2-yl)cyclopropyl]amino}-2-hydroxypropyl)acetamide;~~

N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(4S)-6-(1H-pyrrol-3-yl)-3,4-dihydro-2H-chromen-4-yl]amino}propyl)acetamide;

N-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(6-isopropyl-3,4-dihydro-2H-chromen-4-yl)amino]propyl}acetamide;

~~N-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[1-(3-ethylphenyl)-2-(5-methyl-1,3-oxazol-2-yl)ethyl]amino}-2-hydroxypropyl)acetamide hydrochloride~~

N-[(1S,2R)-1-(3,5-difluorobenzyl)-3-(3,4-dihydro-2H-chromen-4-ylamino)-2-hydroxypropyl]acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(4S)-6-isobutyl-3,4-dihydro-2H-chromen-4-yl]amino}propyl)acetamide;

N-[(1S,2R)-3-{[(4S)-6-cyano-3,4-dihydro-2H-chromen-4-yl]amino}-1-(3,5-difluorobenzyl)-2-hydroxypropyl]acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(4S)-6-neopentyl-3,4-dihydro-2H-chromen-4-yl]amino}propyl)acetamide;

N-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(6-neopentyl-3,4-dihydro-2H-chromen-4-yl)amino]propyl}acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[(4R)-6-(2,2-dimethylpropyl)-3,4-dihydro-2H-

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

PAGE 14/18 * RCVD AT 1/8/2007 1:02:31 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/3 * DNIS:2738300 * CSID:312 913 0002 * DURATION (mm-ss):04-28

BEST AVAILABLE COPY

chromen-4-yl]amino}-2-hydroxypropyl)acetamide;

N-[(1S,2R)-3-{[4-(3-tert-butylphenyl)tetrahydro-2H-pyran-4-yl]amino}-1-(3,5-difluorobenzyl)-2-hydroxypropyl]acetamide;

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[6-(2,2-dimethylpropyl)-1,2,3,4-tetrahydroquinolin-4-yl]amino}-2-hydroxypropyl)acetamide;

N-[(1S,2R)-3-{[(4S)-6-(2,2-dimethylpropyl)-3,4-dihydro-2H-chromen-4-yl]amino}-1-(3-fluorobenzyl)-2-hydroxypropyl]acetamide;

~~N-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[5-(2,2-dimethylpropyl)-2-(1H-imidazol-1-yl)benzyl]amino}-2-hydroxypropyl)acetamide;~~

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-{[6-(2,2-dimethylpropyl)-4-methyl-3,4-dihydro-2H-chromen-4-yl]amino}-2-hydroxypropyl)acetamide;

~~N-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-({1-[3-(3-thienyl)phenyl]cyclohexyl}amino)propyl]acetamide;~~

~~N-[(1S,2R)-1-(3,5-difluorobenzyl)-3-({1-[4-(2,2-dimethylpropyl)pyridin-2-yl]cyclopropyl}amino)-2-hydroxypropyl]acetamide;~~

or a pharmaceutically acceptable salt thereof.

13. (Previously Presented) A method for preparing a compound or salt of

of claim 1, wherein Z, X, R_1, R_2, R_3, R_{15} and R_c are as defined in claim 1, said method comprising

a) reacting an epoxide of the formula



where PG is a nitrogen protecting group that is Cbz, Boc, or benzyl, with a compound of formula $H(R_{15})N\text{-}Rc$, to form a compound of the formula:



;

b) deprotecting the amine to form a compound of the formula:

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

PAGE 15/18 * RCVD AT 1/8/2007 1:02:31 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/3 * DNIS:2738300 * CSID:312 913 0002 * DURATION (mm-ss):04-28

BEST AVAILABLE COPY



c) coupling the deprotected amine with a compound of formula Z-X-LG, where LG is a leaving group, to form a compound of the formula:



14. (Previously Presented) A method of treating a subject who has, Alzheimer's disease (AD); treating subjects with mild cognitive impairment (MCI); treating Down's syndrome; treating subjects who have Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type; treating cerebral amyloid angiopathy and preventing its potential consequences; treating other degenerative dementias; treating dementia associated with Parkinson's disease, progressive supranuclear palsy, or cortical basal degeneration; treating diffuse Lewy body type AD; and frontotemporal dementias with parkinsonism (FTDP), the method comprising administering a therapeutically effective amount of a compound or salt of claim 1 to a person in need of such treatment.

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001

PAGE 16/18 * RCVD AT 1/8/2007 1:02:31 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/3 * DNIS:2738300 * CSID:312 913 0002 * DURATION (mm-ss):04-28

BEST AVAILABLE COPY